Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
Fasano, M Della Corte, C Califano, Raffaele Capuano, A Troiani, T Martinelli, E Ciardiello, F Morgillo, F
Fasano, M
Della Corte, C
Califano, Raffaele
Capuano, A
Troiani, T
Martinelli, E
Ciardiello, F
Morgillo, F
Citations
Altmetric:
Abstract
In recent times, there has been much interest in the development of pharmacological kinase inhibitors that treat NSCLC. Furthermore, treatment options have been guided by the development of a wide panel of synthetic small molecule kinase inhibitors. Most of the molecules developed belong to the type I class of inhibitors that target the ATP-binding site in its active conformation. The high sequence similarity in the ATP-binding site among members of the kinase families often results in low selectivity and additional toxicities. Also, second mutations in the ATP-binding site, such as threonine to methionine at position 790, have been described as a mechanism of resistance to ATP-competitive kinase inhibitors. For these reasons, alternative drug development approaches targeting sites other than the ATP cleft are being pursued. The class III or allosteric inhibitors, which bind outside the ATP-binding site, have been shown to negatively modulate kinase activity.
Description
Date
2014-06
Publisher
Collections
Keywords
Type
Article
Citation
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 2014, 23 (6):809-21 Expert Opin Investig Drugs